Form 4: Seres Therapeutics Director Acquires Stock Options
Statement of Changes in Beneficial Ownership
Director Stephen Berenson of Seres Therapeutics, Inc. acquired stock options for 6,500 shares.
Summary
- Director Stephen Berenson acquired 6,500 stock options for Seres Therapeutics, Inc. common stock.
- The stock options have an exercise price of $7.14 per share.
- The options vest and become exercisable on the earlier of July 8, 2027, or the day before the first annual stockholder meeting after July 8, 2026.
- The transaction date was July 8, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it reports a routine stock option grant to a director rather than significant financial results or strategic shifts.
Positives
- Director acquisition of stock options can signal confidence in the company's future prospects.
- The acquisition of options at a specific exercise price indicates a defined potential future cost for acquiring shares.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a transaction related to stock options.
Industry Context
StockSavvy.ai notes that director acquisitions of stock options are common in the biotechnology sector as a form of executive compensation and incentive, aligning management's interests with shareholders.
Stakeholder Impact
- Shareholders: The acquisition of options by a director may be viewed positively as it aligns management's interests with long-term shareholder value, though it does not immediately impact share count or value.
Key Dates
| Date | Description |
|---|---|
| 07/08/2026 | Earliest transaction date and transaction date for stock option acquisition. |
| 07/07/2036 | Expiration date of the stock options. |
| 07/08/2027 | Vesting date for stock options (earlier of this date or day before first annual meeting after 07/08/2026). |
| 07/10/2026 | Date of signature for the filing. |
Keywords
Seres Therapeutics, MCRB, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.